PortfoliosLab logoPortfoliosLab logo
DNLI vs. ALMS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

DNLI vs. ALMS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Denali Therapeutics Inc. (DNLI) and Alumis Inc (ALMS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, DNLI achieves a 50.03% return, which is significantly lower than ALMS's 151.13% return.


DNLI

1D
2.99%
1M
32.89%
YTD
50.03%
6M
47.35%
1Y
81.86%
3Y*
-5.03%
5Y*
-19.54%
10Y*

ALMS

1D
-0.37%
1M
11.31%
YTD
151.13%
6M
114.06%
1Y
775.36%
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

DNLI vs. ALMS - Yearly Performance Comparison


2026 (YTD)20252024
DNLI
Denali Therapeutics Inc.
50.03%-18.99%-11.28%
ALMS
Alumis Inc
151.13%24.17%-41.78%

Correlation

The correlation between DNLI and ALMS is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Jun 28, 2024

0.24

Fundamentals

Market Cap

DNLI:

$4.62B

ALMS:

$3.06B

EPS

DNLI:

-$2.88

ALMS:

-$2.31

PB Ratio

DNLI:

4.99

ALMS:

5.41

Total Revenue (TTM)

DNLI:

$0.00

ALMS:

$8.40M

Gross Profit (TTM)

DNLI:

-$2.87M

ALMS:

$5.79M

EBITDA (TTM)

DNLI:

-$526.60M

ALMS:

-$411.89M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Denali Therapeutics Inc.

Alumis Inc

Return for Risk

DNLI vs. ALMS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNLI
DNLI Risk / Return Rank: 8282
Overall Rank
DNLI Sharpe Ratio Rank: 8282
Sharpe Ratio Rank
DNLI Sortino Ratio Rank: 7878
Sortino Ratio Rank
DNLI Omega Ratio Rank: 7575
Omega Ratio Rank
DNLI Calmar Ratio Rank: 8989
Calmar Ratio Rank
DNLI Martin Ratio Rank: 8585
Martin Ratio Rank

ALMS
ALMS Risk / Return Rank: 9999
Overall Rank
ALMS Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
ALMS Sortino Ratio Rank: 9999
Sortino Ratio Rank
ALMS Omega Ratio Rank: 9898
Omega Ratio Rank
ALMS Calmar Ratio Rank: 9999
Calmar Ratio Rank
ALMS Martin Ratio Rank: 9999
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNLI vs. ALMS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Denali Therapeutics Inc. (DNLI) and Alumis Inc (ALMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


DNLIALMSDifference
Sharpe ratioReturn per unit of total volatility

-4.98

Sortino ratioReturn per unit of downside risk

-4.41

Omega ratioGain probability vs. loss probability

1.25

1.83

-0.58

Calmar ratioReturn relative to maximum drawdown

4.02

21.36

-17.34

Martin ratioReturn relative to average drawdown

7.97

55.78

-47.82

DNLI vs. ALMS - Sharpe Ratio Comparison

The current DNLI Sharpe Ratio is 1.44, which is lower than the ALMS Sharpe Ratio of 6.42. The chart below compares the historical Sharpe Ratios of DNLI and ALMS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

DNLI vs. ALMS - Drawdown Comparison

The maximum DNLI drawdown since its inception was -87.74%, which is greater than ALMS's maximum drawdown of -79.26%. Use the drawdown chart below to compare losses from any high point for DNLI and ALMS.


Loading charts...

Drawdown Indicators


DNLIALMSDifference

Max Drawdown

Largest peak-to-trough decline

-87.74%

-79.26%

-8.48%

Max Drawdown (1Y)

Largest decline over 1 year

-20.49%

-36.66%

+16.17%

Max Drawdown (3Y)

Largest decline over 3 years

-63.68%

Max Drawdown (5Y)

Largest decline over 5 years

-85.38%

Current Drawdown

Current decline from peak

-73.53%

-18.25%

-55.28%

Average Drawdown

Average peak-to-trough decline

-51.61%

-38.42%

-13.19%

Ulcer Index

Depth and duration of drawdowns from previous peaks

10.31%

14.01%

-3.70%

Volatility

DNLI vs. ALMS - Volatility Comparison

The current volatility for Denali Therapeutics Inc. (DNLI) is 14.88%, while Alumis Inc (ALMS) has a volatility of 21.24%. This indicates that DNLI experiences smaller price fluctuations and is considered to be less risky than ALMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


DNLIALMSDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.88%

21.24%

-6.36%

Volatility (6M)

Calculated over the trailing 6-month period

41.18%

85.49%

-44.31%

Volatility (1Y)

Calculated over the trailing 1-year period

57.29%

121.95%

-64.66%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

62.51%

116.10%

-53.59%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

65.13%

116.10%

-50.97%

Dividends

DNLI vs. ALMS - Dividend Comparison

Neither DNLI nor ALMS has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

DNLI vs. ALMS - Financials Comparison

This section allows you to compare key financial metrics between Denali Therapeutics Inc. and Alumis Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M202220232024202520260
1.74M
(DNLI) Total Revenue
(ALMS) Total Revenue
Values in USD except per share items

Frequently Asked Questions


DNLI and ALMS have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ALMS has higher volatility (21.24%) compared to DNLI (14.88%). In terms of maximum drawdown, DNLI dropped -87.74% vs ALMS's -79.26%.

ALMS currently has the higher Sharpe Ratio (6.42 vs 1.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for DNLI and ALMS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer